Quest Diagnostics Incorporated (DGX)

Market Cap	16.91B
Revenue (ttm)	9.54B
Net Income (ttm)	838.00M
Shares Out	111.62M
EPS (ttm)	7.44
PE Ratio	20.35
Forward PE	16.02
Dividend	$3.00 (1.98%)
Ex-Dividend Date	Jan 14, 2025

Volume	114,302
Open	151.83
Previous Close	152.63
Day's Range	150.28 - 152.26
52-Week Range	123.04 - 165.32
Beta	0.89
Analysts	Buy
Price Target	168.14 (+11.01%)
Earnings Date	Jan 30, 2025

About DGX

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, govern...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Dec 17, 1996
• Employees: 48,000
• Stock Exchange: NYSE
• Ticker Symbol: DGX
• Website: https://www.questdiagnostics.com

Financial Performance

In 2023, Quest Diagnostics's revenue was $9.25 billion, a decrease of -6.38% compared to the previous year's $9.88 billion. Earnings were $850.00 million, a decrease of -9.77%.

Analyst Forecast

According to 14 analysts, the average rating for DGX stock is "Buy." The 12-month stock price forecast is $168.14, which is an increase of 11.01% from the latest price.

Price Target

$168.14

(11.01% upside)

Analyst Consensus: Buy